Austrália - inglês - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: sodium hydroxide; water for injections; metacresol; protamine sulfate; dibasic sodium phosphate heptahydrate; phenol; glycerol; zinc oxide; hydrochloric acid - indications: for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: hydrochloric acid; glycerol; phenol; water for injections; dibasic sodium phosphate heptahydrate; metacresol; zinc oxide; sodium hydroxide; protamine sulfate - indications: for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis. for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: protamine sulfate; phenol; hydrochloric acid; glycerol; metacresol; sodium hydroxide; zinc oxide; water for injections; dibasic sodium phosphate heptahydrate - for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, suspension - excipient ingredients: zinc oxide; sodium hydroxide; hydrochloric acid; dibasic sodium phosphate heptahydrate; protamine sulfate; phenol; glycerol; water for injections; metacresol - for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, solution - excipient ingredients: hydrochloric acid; sodium hydroxide; dibasic sodium phosphate heptahydrate; water for injections; zinc oxide; glycerol; metacresol - indications: for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Austrália - inglês - Department of Health (Therapeutic Goods Administration)

eli lilly australia pty ltd - insulin lispro, quantity: 100 iu/ml - injection, solution - excipient ingredients: hydrochloric acid; dibasic sodium phosphate heptahydrate; glycerol; metacresol; zinc oxide; sodium hydroxide; water for injections - for the treatment of patients with type i (iddm) and type ii (niddm) diabetes mellitus who require insulin for the maintenance of normal glucose homeostasis.

Estados Unidos - inglês - NLM (National Library of Medicine)

imclone llc - insulin lispro (unii: gfx7qis1ii) (insulin lispro - unii:gfx7qis1ii) - insulin lispro injection is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. insulin lispro injection is contraindicated: - during episodes of hypoglycemia - in patients who are hypersensitive to insulin lispro injection or to any of its excipients. risk summary the limited available data with insulin lispro injection in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. published studies with insulin lispro used during pregnancy have not reported an association between insulin lispro and the induction of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . pregnant rats and rabbits were exposed to insulin lispro in animal reproduction studies during organogenesis. no adverse effects on embryo/fetal viability or morphology were obser

Estados Unidos - inglês - NLM (National Library of Medicine)

novo nordisk pharma, inc. - insulin aspart (unii: d933668qvx) (insulin aspart - unii:d933668qvx) - insulin aspart is indicated to improve glycemic control in adults and pediatric patients with diabetes mellitus. insulin aspart is contraindicated: risk summary available information from published randomized controlled trials with insulin aspart use during the second trimester of pregnancy have not reported an association with insulin aspart and major birth defects or adverse maternal or fetal outcomes [see data] . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy [see clinical considerations] . in animal reproduction studies, administration of subcutaneous insulin aspart to pregnant rats and rabbits during the period of organogenesis did not cause adverse developmental effects at exposures 8-times and equal to the human subcutaneous dose of 1 unit/kg/day, respectively. pre- and post-implantation losses and visceral/skeletal abnormalities were seen at higher exposures, which are considered secondary to maternal hypoglycemia. these effects were similar to those o

Estados Unidos - inglês - NLM (National Library of Medicine)

remedyrepack inc. - insulin lispro (unii: gfx7qis1ii) (insulin lispro - unii:gfx7qis1ii) - insulin lispro injection is a rapid acting human insulin analog indicated to improve glycemic control in adults and children with diabetes mellitus. insulin lispro injection is contraindicated: - during episodes of hypoglycemia - in patients who are hypersensitive to insulin lispro injection or to any of its excipients. risk summary the limited available data with insulin lispro injection in pregnant women are insufficient to inform a drug-associated risk of adverse developmental outcomes. published studies with insulin lispro used during pregnancy have not reported an association between insulin lispro and the induction of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . pregnant rats and rabbits were exposed to insulin lispro in animal reproduction studies during organogenesis. no adverse effects on embryo/fetal

Estados Unidos - inglês - NLM (National Library of Medicine)

eli lilly and company - insulin lispro (unii: gfx7qis1ii) (insulin lispro - unii:gfx7qis1ii) - insulin lispro is indicated to improve glycemic control in adult and pediatric patients with diabetes mellitus. insulin lispro is contraindicated: - during episodes of hypoglycemia [see warnings and precautions (5.3)] . - in patients who are hypersensitive to insulin lispro or to any of the excipients in insulin lispro [see warnings and precautions (5.5)] . risk summary published studies with insulin lispro used during pregnancy have not reported an association between insulin lispro and the induction of major birth defects, miscarriage, or adverse maternal or fetal outcomes (see data) . there are risks to the mother and fetus associated with poorly controlled diabetes in pregnancy (see clinical considerations) . pregnant rats and rabbits were exposed to insulin lispro in animal reproduction studies during organogenesis. no adverse effects on embryo/fetal viability or morphology were observed in offspring of rats exposed to insulin lispro at a dose approximately 3 times the human subcutaneous dose of 1 unit i